Roche Glycart AG Dominic Schwarz – ESR9 – is hosted by the Roche Innovation Center Zürich under the supervision of Christian Klein Roche Innovation Center Zurich is Roche Pharma Research and Early Development’s (pRED) Center of Excellence for Cancer Immunotherapy. One major focus is the development of engineered antibodies that address unmet clinical needs. Roche Innovation Center Zurich is one of Roche’s antibody engineering powerhouses. Glycart Biotechnology AG was initially established in September 2000 as a spin-off of the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. In the summer of 2005, it was acquired by the Roche Group and integrated in Roche Pharma Research and Early Development (pRED). The state of the art research complex based in Schlieren, Switzerland, is now an integral part of Roche Pharma Research and Early Development. Roche Innovation Center Zurich is one of seven Roche Pharma Research and Early Development Innovation Centers. It boasts a multinational team of some 185 employees – many of whom are research scientists – with a dynamic, thriving biotech culture. Roche Innovation Center Zurich is headed by Dr Pablo Umaña and comprises of research teams in diverse fields including cancer immunotherapy discovery, pharmacology, molecular biology, cell and protein engineering, process biochemistry, cell biological assays, and histology. The teams belong to the oncology DTA Discovery, Early Development Oncology and global functions including Large Molecule Research, Pharmaceutical Sciences, Data & Analytics, and Operations. Roche Innovation Center Zurich focuses on product development – from scientific concepts and validation to the corresponding studies. Today the compounds studied and developed are boosting Roche’s significant commitment towards offering improved cancer medicines.
Network for Optimizing Adoptive T cell Therapy (T-OP)’s Post
More Relevant Posts
-
During her secondment at Miltenyi Biotec headquarters in Bergisch Gladbach, ESR 11 Laura Marcos Kovandzic cooperated with ESR 13 Valeria Durante to perform experiments using the MACSima™ system. Miltenyi Biotec’s MICS (MACSima™ Imaging Cyclic Staining) technology enables the simultaneous analysis of hundreds of markers on a single sample. Based on fluorescence microscopy, it uses the principle of cyclic staining with different fluorochrome-conjugated antibodies to acquire microscopy data for a multitude of parameters without harming the sample. The cyclic process includes three main steps, all conducted automatically by the MACSima™ System. As part of her PhD project, which focuses on studying the impact of gut microbiota on the efficacy of CAR-T cell therapy, Laura and Valeria collaborated through all phases of the experiment. This included antibody panel design, experiment preparation and execution, and analysis of the results using MACS® iQ View iQ View Spatial Biology software. Their aim was to determine the level of CAR-T cell infiltration and proliferation, and to further assess the phenotype of the various infiltrating cells in different treatment groups of samples from in vivo experiments performed in mice. #cancer #research #eu #mariecurie #network
-
-
On Monday and Tuesday of our meeting in Paris, the focus was on the individual presentations of us PhD students. Valuable insights were provided and constructive feedback was given for which we are very grateful. Monday evening we were able to enjoy the delights of French cuisine at a jointly organized dinner. Tuesday evening we went to a career evening to find out about new career opportunities after the PhD. With Laura LAUDEN (Head of Grant Office at Gustave Roussy), Héloïse Dufour (Director LE CERCLE FSER), Renaud Pourpre, PhD (Founder of Explorer), and Luca Danelli (Senior Editor of Nature Communications), this time there was a greater focus on careers outside the academic spectrum. We would like to thank you very much! You gave us valuable tips and insights into several completely different opportunities! #career #science #paris
-
-
Last Thursday and Friday our conference “Improving Adoptive Cell Therapy” took place in Paris. We would like to thank Camille Bigenwald, Laurie Menger, Laura Marcos Kovandzic, and Laurence Zitvogel for the organization. We would also like to congratulate Johanna Nimmerfroh and Mar Guaza Lasheras for the best posters and Ulrika Bader for the best short talk. However, this would never have been possible without our speakers and therefore special thanks go to you! - Florent Ginhoux Jerome Galon Cécile Alanio Julie Helft Robert Majzner Katy Rezvani sebastian amigorena Alena Gros Vidal Michel Sadelain Alex Marson Laurie Menger Suman Mitra Rahul Roychoudhuri Justin Eyquem Claire Roddie and Luca Gattinoni We hope everyone who attended enjoyed the event! Hope to see you next year in Amsterdam (with different microphones then, we promise! 😉).
-
-
The next ITOC Conference will take place from Thu. 21st to Sat. 23rd March 2024, register now! https://lnkd.in/dskSnMhc
-
Explore the future of adoptive cell therapy at our congress, where experts converge to improve and shape the forefront of cell therapies! On 30.05-31.05.2024 our further conference "Improving adoptive cell therapy" will take place in Paris. Also this year we welcome successful scientists from all over the world. Tickets and the exact program are available here. https://lnkd.in/evi9yA-r #conference #paris #cancerresearch #cancer #celltherapy
-
-
LMU Munich – Ludwig-Maximilians-Universität München – ESR1 & ESR8 David Andreu Sanz (ESR1) and Emanuele Carlini (ESR8) are hosted by the Ludwig Maximilian University of Munich (LMU), within its Division of Clinical Pharmacology, whose primary objective is to better understand mechanisms of the innate and of the adaptive immune system in order to develop new immune-based therapies. In particular, the two PhD students belong to the ‘Immunopharmacology’ research group of Professor Sebastian Kobold. In the context of T-OP, Professor Kobold’s research focuses on engineering T lymphocytes with Chimeric Antigen Receptors (CAR). His group strives to develop approaches to improve the T cells’ ability to approach and kill tumor cells by enhancing tumor infiltration and by-passing common pathways of antigen escape and local immunosuppression. #cancer #pharmacology #tcells #fda #ema #mariecurie #eu
-
-
Check out the latest publication of our Network by Fabian Richter entitled "STING-driven activation of T cells: relevance for the adoptive cell therapy of cancer" https://lnkd.in/eamBTg2z #mariecurie #cancer #therapy #publication
STING-driven activation of T cells: relevance for the adoptive cell therapy of cancer
https://www.cell-stress.com
-
Congratulations Catarina Guerra on your recent review article, "Engineering strategies to optimise adoptive cell therapy in ovarian cancer". Check it out here! https://lnkd.in/eJu3n56v #publication #article #mariecurie #cancer #ACT
Engineering strategies to optimise adoptive cell therapy in ovarian cancer
sciencedirect.com
-
Last week we met for our fourth workshop in Munich. It was great to get together again, exchange ideas, and learn new methods. Here are a few impressions from the workshops of the past week: #Munich #workshop #mariecurie
-
